MiraDx is committed to discovering meaningful ways to better treat cancer in patients with mutations like and including the KRAS-variant
We are developing answers by applying our novel class of functional, germ-line genetic markers in the following areas:
Radiation therapy is a form of cancer treatment that is used in over 2/3 of cancer patients diagnosed every year. Although generally, radiation is a safe treatment, 5-10% of patients will experience serious side effects from treatment. In addition, some patients respond not only locally to radiation, but also have an immune response that can help them to fight their cancer.
Miradx is at the forefront in this field, with a leading radiogenomics program, applying our class of microRNA binding site mutations to identify patients that respond differently to radiation. Our first publication on this problem found that patients with the KRAS-variant have a weak immune response to radiation, requiring the addition of cetuximab to help (Jama Oncology, 2016).
Contact us if you're interested in partnering with us on Radiogenomics.
Cancer systemic therapy
Although it is completely logical that inherited, germ-line genetic differences, present in all cells, including those of the immune system, will predict response and toxicity to developing immune therapies, there has been little study of the genomic areas studied by MiraDx to find such biomarkers. MiraDx discovered a panel of such mutations that predict both response and toxicity to anti-PD1 and anti-PDL1 therapies currently on the market. We are working with potential partners to incorporate these findings into the newer agents to allow better patients selection to achieve improved response and less toxicity from these exciting new therapies. We are additionally working with partners to apply these mutations to all classes of developing immunotherapies. For interested partners, please feel free to contact us at email@example.com.
In addition, we are currently offering the panel to predict toxicity, ImuDx, to physicians interested in this information for better managing their patients. If you would like to join our studies on ImuDx, please contact us at firstname.lastname@example.org.
Head and Neck Squamous Cell Carcinoma
Studies have definitively shown that KRAS-variant head and neck cancer patients respond differently to targeted agents used in standard treatment. Specifically, Cetuximab is an excellent choice for treatment. We are currently working towards additional collaborative studies to better define the time course and dosing, to make this the standard of care for these patients.
Non-Small Cell Lung Cancer
Physicians and researchers at MDACC and Yale University have evaluated the association between treatment response for NSCLC patients in the BATTLE trials and the KRAS-variant. Results from these studies suggest that KRAS-variant patients respond to certain drugs, such as Sorafenib, and not others, such as Gefitinib, used in metastatic lung cancer.
Studies show that standard treatment consisting of Platinum compounds work poorly for ovarian cancer patients with the KRAS-variant. We hope to define the best strategy for these patients, as the KRAS-variant is found in 1 of 4 newly diagnosed ovarian cancer patients.